AZTA

AzentaF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

30%

Probability

Target price

$26.00

+8.8% vs current

Most likely

Base case

45%

Probability

Target price

$19.00

-20.5% vs current

B-

Bear case

25%

Probability

Target price

$14.00

-41.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Primary-source tone turned materially weaker on May 5-8, 2026 as Azenta reported a Q2 miss, cut FY26 organic growth, margin, and free-cash-flow expectations, and then confirmed in the 10-Q that the B Medical buyer had not secured financing by March 31. Using the packet's anchor, shares closed at $18.57 on May 7, 2026, well below the roughly mid-$24 level referenced in immediate post-release coverage, suggesting the negative reaction largely held through the T+3 follow-up. Fresh analyst revision evidence was thin in checked sources, so this remains a cautious monitoring setup rather than a high-conviction rebound call.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-05catalystQ2 miss and FY26 guidance reset keep near-term pressure on the setupHigh impact

Azenta's May 5 earnings release showed fiscal Q2 revenue of $145 million, organic revenue down 3% year over year, adjusted EBITDA margin of 5.4%, and a FY26 reset to roughly down 2% to up 1% organic growth with weaker margin and free-cash-flow expectations; management also pushed the long-range plan to 2029 from 2028 [#8-K-2026-05-05].

2026-05-08eventThe March 31 10-Q confirmed the B Medical sale financing problem and added downside contingency riskMedium impact

The 10-Q said buyer Thelema had not secured financing by March 31, 2026, the transaction did not close, either party may terminate the agreement, and Azenta would retain $5.0 million of the $9.0 million deposit as a break-up fee if terminated; the filing also warned prolonged delay or failure could dilute results and distract management from the core SMS and Multiomics businesses [#10-Q-2026-05-08].

2026-09-30catalystTurnaround execution in Multiomics and core operations is the main recovery path into fiscal year-endHigh impact

Management said 2026 priorities are to transform Multiomics, strengthen commercial execution, optimize the operating footprint, and improve productivity through the Azenta Business System, while the 10-Q shows adequate liquidity at $564.8 million of cash, restricted cash, and marketable securities to fund the effort; still, the recovery has to offset weaker North America demand, Automated Stores rework, and inventory reserve pressure before the reset can re-rate [#8-K-2026-05-05] [#10-Q-2026-05-08] [#10-K-2025-12-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology